• Latest Posts
In Depth 19 Oct 2023

Biotech’s battle against NASH: The ongoing pursuit of an effective treatment

In Depth 11 Dec 2023

European patents in biotech: how to prevent invalid patents?

In Depth 15 Nov 2023

Beyond oil and gas: Biotech’s significant place in the Qatar Investment Authority’s strategy

In Depth 7 Dec 2023

The biggest private biotech investments in November 2023

In Depth 30 Nov 2023

Could an Alzheimer’s vaccine make treatment more affordable?

ADVERTISEMENT
In Depth 27 Nov 2023

How are R&D Tax Incentives shaping Australia’s biotech future?

In Depth 23 Nov 2023

The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy

In Depth 22 Nov 2023

Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment

In Depth 16 Nov 2023

Meet the ‘biotech mafia’: how specialized biotech VC firms are dominating industry funding once again

In Depth 9 Nov 2023

Blood tests for Alzheimer’s: a hit or a miss?

In Depth 8 Nov 2023

Promising cure for COPD: is a breakthrough treatment within reach?

ADVERTISEMENT